<DOC>
	<DOCNO>NCT01181505</DOCNO>
	<brief_summary>This study investigate pharmacokinetics tolterodine , substrate CYP2D6 healthy subject relation presence HNF-4A G60D variant .</brief_summary>
	<brief_title>STUDY The Effect HNF-4A G60D Variant In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study</brief_title>
	<detailed_description>After single oral administration 2 mg tolterodine 31 healthy subject ( 6 heterozygous mutation HNF-4A G60D vs 25 subject wild type whose CYP2D6 genotype gender match variant group ) , blood collect 24hrs . Assay tolterodine metabolite , 5-hyroxymethyl tolterodine conduct use LC/MS/MS .</detailed_description>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>Healthy subject whose HNF4a CYP2D6 genotype ware determine Subject whose HNF4a CYP2D6 genotype ware determine</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>HNF4a</keyword>
	<keyword>CYP2D6</keyword>
	<keyword>Toterodine</keyword>
	<keyword>Genetic polymorphism</keyword>
</DOC>